For research use only. Not for therapeutic Use.
Eciruciclib is an antineoplastic and potent cyclin dependent kinase (CDK) inhibitor[1].
| Catalog Number | I045113 |
| CAS Number | 1868086-40-1 |
| Synonyms | N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(2-methyl-3-propan-2-ylindazol-5-yl)pyrimidin-2-amine |
| Molecular Formula | C27H33FN8 |
| Purity | ≥95% |
| InChI | InChI=1S/C27H33FN8/c1-5-35-10-12-36(13-11-35)17-19-6-9-24(29-15-19)31-27-30-16-22(28)25(32-27)20-7-8-23-21(14-20)26(18(2)3)34(4)33-23/h6-9,14-16,18H,5,10-13,17H2,1-4H3,(H,29,30,31,32) |
| InChIKey | RLRQXKXWZNPYRB-UHFFFAOYSA-N |
| SMILES | CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(N(N=C5C=C4)C)C(C)C)F |
| Reference | [1]. WHO Drug Information, Vol. 35, No. 4, 2021. Geneva: World Health Organization; 2022. |
